An Open-label Multicenter Phase 1b Study of JNJ-63723283 a PD-1 Inhibitor Administered in Combination with Apalutamide in Subjects with Metastatic Castration-Resistant Prostate Cancer

Brief description of study

If you have been diagnosed with Metastatic Castration-Resistant Prostate Cancer, you may be qualified for this Phase 1b study. The main goal of the study is to find out how safe and effective the investigational drug JNJ-63723283 and apalutamide (ERLEADA) are when given together to treat patients with prostate cancer. JNJ-63723283 is a new PD-1 inhibitor that is being developed as an immunotherapy.

Clinical Study Identifier: s18-00360 Identifier: NCT03551782
Principal Investigator: David R. Wise
Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.